Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 77

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 77
---
 revenue may be 
 adversely affected, and our business may suffer.                                                      |

5

| • |     | We currently have no marketing and sales organization and have no experience as a company in commercializing                                                                                                                                            
 products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able 
 to generate product revenue.                                                                                                                                                                                                                            |

| • |     | Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject 
 to additional regulatory burdens and other risks and uncertainties.                                            |

Risks Related to Our Business Operations and Industry

| • |     | Our operating results may fluctuate significantly, which makes our future operating results difficult to 
 predict and could cause our operating results to fall below expectations or any guidance we may provide. |

| • |     | We are dependent on the services of our management and other clinical and scientific personnel, and if we are                         
 not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. |

| • |     | We may encounter difficulties in managing our growth and expanding our operations successfully. |

| • |     | If we have multiple Product Candidates in our clinical pipeline and if we consider a variety of target                                                                                                                                   
 indications, we may expend our limited resources to pursue a particular Product Candidate and fail to capitalize on Product Candidates or indications that may be more profitable or for which there is a greater likelihood of success. |

| • |     | We have incurred and may continue to incur significant costs for our clinical trials for our Product 
 Candidates.                                                                                          |

| • |     | We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act (the “FCPA”) and                                                                                                                                                           
 similar anti-corruption and anti-bribery laws of the PRC and other countries in which we operate, as well as U.S. and foreign export controls, trade sanctions and import laws and regulations. Compliance with these legal requirements could limit our 
 ability to compete in foreign markets and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.                                                                                     |

| • |     | We are subject to various foreign, federal, and state healthcare laws and regulations, and failure to comply 
 with these laws and regulations could harm our results of operations and financial condition.                |

| • |     | Actual or perceived failures